BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AlphaVax, Inc. Announces Nomination for 2012 Vaccine Industry Excellence Award


3/21/2012 9:43:44 AM

RESEARCH TRIANGLE PARK, N.C., March 20, 2012 /PRNewswire/ -- AlphaVax, Inc. ("AVX") is pleased to report that it has been selected as a corporate nominee for the 2012 Vaccine Industry Excellence Award as the Best Early-Stage Vaccine Biotech Company. The award will be announced during the World Vaccine Congress meeting in Washington, DC in April.

AVX is pleased to be both included in the list of finalists as deemed by the panel of judges as well as being recognized as a leader in the field. The Company's proprietary replicon technology has been tested in several clinical trials involving approximately 400 patients. In concert with the Duke University Medical Center in Durham, NC, AVX is awaiting the initiation of a Phase I trial in HER2+ breast cancer.

About AlphaVax
Based in Research Triangle Park, NC, AVX has developed a new generation of vaccine products for diseases that represent significant market opportunities based on its novel, proprietary vector platform technology. AlphaVax is at the forefront of a completely new class of potent biopharmaceutical products aimed to participate in this market with its viral vector technology that has the clear potential to redefine the traditional concept of vaccines. The AlphaVax proprietary viral vector gene expression system has the potential for developing a range of effective vaccines in both cancer and infectious disease.

AlphaVax is focusing the commercial potential of its alphavaccine system in cancer immunotherapy. The development of immunotherapeutic treatments for cancer is a rapidly growing area in which AlphaVax will be taking a lead position in developing new treatment modalities utilizing its proprietary technology.

SOURCE AlphaVax, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES